Dr Daver talks to ecancer at EHA 2017 about how blocking PD-1/PD-L1 pathways enhances anti-leukaemia responses in murine AML.
PD-1 positive CD8 T-cells are increased in bone marrow of patients with AML.
Azacytidine up-regulates PD-1 and interferon-gamma signaling in AML and the up-regulation of PD-1 has been associated with emergence of resistance to azacytidine.
He states that full dose AZA and nivolumab are tolerable and produce an encouraging response rate with durable responses in relapsed AML with poor risk features.
